MK-5108 (VX689)

Description: MK-5108 (also known as VX-689) is a novel, specific and ATP-competitive inhibitor of Aurora A kinase with potential anticancer activity. It inhibits Aurora A kinase with an IC50 of 0.064 nM in a cell-free assay. MK-5108 also less potently inhibits other Aurora kinases, including Aurora B kinase (IC50 = 14 nM) and Aurora C kinase (IC50 = 12 nM). MK-5108 has been found to exhibit antitumor activity in a wide range of cancer types, including breast, cervix, colorectal, ovary and pancreas neoplasms.

References: Mol Cancer Ther. 2010 Jan; 9(1):157-66; Clin Cancer Res. 2012 Jun 15; 18(12):3352-65.

VX-689; VX689; VX 689; MK5108; MK-5108; MK 5108; VX-689

Chemical Name: (1r, 4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid

InChi Key: LCVIRAZGMYMNNT-VVONHTQRSA-N

InChi Code: InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15, 20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6, 11-12, 15H, 7-10, 13H2, (H, 28, 29)(H, 25, 26, 27)/t15-, 22-

SMILES Code: O=C([C]1(CC2=NC(NC3=NC=CS3)=CC=C2)CC[CH](OC4=CC=CC(Cl)=C4F)CC1)O